WellDoc(R), developers of BlueStar(TM), the first mobile prescription therapy for type 2 diabetes, today announced it will present the initial results of its hypoglycemia prediction model at the 2013 Diabetes Technology Society Meeting. The model has demonstrated the ability to predict hypoglycemia (a dangerously low blood sugar level) in patients with type 2 diabetes. By using seven days of spot blood glucose monitoring data, with about one blood glucose test per day, the WellDoc prediction model can alert for hypoglycemic events that are likely to occur within the next 24 hours. The methodology for the research will be presented during the scientific poster session at the Diabetes Technology Meeting in San Francisco on October 31.
Hypoglycemia is one of the most dangerous, costly, and difficult diabetes complications to manage. A recent study(1) of 2.4 million type 2 diabetes patients found that hypoglycemia was especially common in patients treated with insulin or sulfonylureas with costs for a hypoglycemia related hospital event averaging $10,362, regardless of a patient’s drug regimen. A 2005 study(2) further reported that patients who had experienced hypoglycemia had 77 percent more disability days per year.